What is ProfoundBio?
ProfoundBio operates at the intersection of biotechnology and precision medicine, specializing in the discovery and development of novel antibody-drug conjugates and therapeutic candidates. The company maintains a diverse pipeline that spans discovery, preclinical, and clinical stages, targeting a wide array of tumor types. With a focus on curative potential, ProfoundBio utilizes proprietary technology platforms to address significant unmet medical needs, effectively bridging the gap between laboratory innovation and clinical application. Its market position is reinforced by a disciplined approach to scientific validation and a commitment to improving patient outcomes through targeted, high-efficacy biotherapeutics.
How much funding has ProfoundBio raised?
ProfoundBio has raised a total of $247M across 3 funding rounds:
Other Financing Round
$10M
Series A
$125M
Series B
$112M
Other Financing Round (2021): $10M with participation from Xianfeng Qiyun
Series A (2022): $125M led by Oriza, Lilly Asia Ventures, and Sequoia China
Series B (2024): $112M supported by Janus Henderson Investors, RA Capital Management, Ally Bridge Group, and Nextech Invest
Key Investors in ProfoundBio
Lilly Asia Ventures
Lilly Asia Ventures is a leading biomedical venture capital firm with a focus on building breakthrough companies that develop products to treat diseases and improve human health.
RA Capital Management
RA Capital Management is a multi-stage investment manager focused on evidence-based investing in public and private healthcare and life science companies.
Ally Bridge Group
Ally Bridge Group is a global healthcare investment firm specializing in high-impact life science innovation and managing significant transactions across the healthcare sector.
What's next for ProfoundBio?
With the successful closure of its latest financing round, ProfoundBio is well-positioned to accelerate its clinical development programs and expand its research capabilities. The infusion of capital will likely support the advancement of its lead candidates through critical trial phases, further validating its innovative antibody platforms. As the company transitions into a more mature operational phase, strategic priorities will likely include scaling its internal R&D infrastructure, pursuing potential collaborative partnerships, and navigating the regulatory pathways necessary to bring its pipeline to market. The continued support from top-tier life science investors signals strong market confidence in the company's long-term potential to redefine standards of care in oncology.
See full ProfoundBio company page
